nexlizet

Generic: bempedoic acid and ezetimibe

nexlizet: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
Esperion Therapeutics, Inc. (ESPR)Approved

FDA Decisions

Approval1 INDICATIONS AND USAGE NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Bempedoic acid, a component of NEXLIZET, is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unabl(ESPR)

Frequently asked questions

Who is developing nexlizet?

nexlizet is being developed by Esperion Therapeutics, Inc..

What is nexlizet's latest FDA decision?

The most recent tracked FDA decision for nexlizet is Approval for 1 INDICATIONS AND USAGE NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Bempedoic acid, a component of NEXLIZET, is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unabl, dated February 26, 2020.

Get deeper analysis on nexlizet

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    nexlizet — Drug Pipeline, Trials & FDA Status | BioSniper